Abstract
Background: Human dihydroorotate dehydrogenase (hDHODH, EC 1.3.5.2), a flavindependent mitochondrial enzyme involved in de novo pyrimidine biosynthesis, is a validated therapeutic target for the treatment of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. However, human DHODH inhibitors have also been investigated as treatment for cancer, parasite infections (i.e. malaria) and viruses as well as in the agrochemicals industry.
Objective: An overview of current knowledge of hDHODH inhibitors and their potential uses in diseases where hDHODH is involved.
Method: This review focuses on recent advances in the development and application of hDHODH inhibitors, specifically covering the patent field, starting from a brief description of enzyme topography and of the strategies usually followed in designing its selective inhibitors.
Results: The most important and well-described novelty is the fact that the discovery, in the autumn of 2016, that hDHODH inhibitors are able to induce in vivo myeloid differentiation has led to the possibility of developing novel hDHODH based treatments for Acute Myelogenous Leukemia (AML).
Conclusion: The review will describe a variety of specific inhibitor classes and conclude on recent and future therapeutic perspectives for this target.
Keywords: Autoimmune diseases, brequinar, cancer, dihydroorotate dehydrogenase (DHODH), inhibitors, leflunomide, leukemia, melanoma.
Recent Patents on Anti-Cancer Drug Discovery
Title:Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy
Volume: 13 Issue: 1
Author(s): Marco L. Lolli, Stefano Sainas, Agnese C. Pippione, Marta Giorgis, Donatella Boschi and Franco Dosio*
Affiliation:
- Department of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin,Italy
Keywords: Autoimmune diseases, brequinar, cancer, dihydroorotate dehydrogenase (DHODH), inhibitors, leflunomide, leukemia, melanoma.
Abstract: Background: Human dihydroorotate dehydrogenase (hDHODH, EC 1.3.5.2), a flavindependent mitochondrial enzyme involved in de novo pyrimidine biosynthesis, is a validated therapeutic target for the treatment of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. However, human DHODH inhibitors have also been investigated as treatment for cancer, parasite infections (i.e. malaria) and viruses as well as in the agrochemicals industry.
Objective: An overview of current knowledge of hDHODH inhibitors and their potential uses in diseases where hDHODH is involved.
Method: This review focuses on recent advances in the development and application of hDHODH inhibitors, specifically covering the patent field, starting from a brief description of enzyme topography and of the strategies usually followed in designing its selective inhibitors.
Results: The most important and well-described novelty is the fact that the discovery, in the autumn of 2016, that hDHODH inhibitors are able to induce in vivo myeloid differentiation has led to the possibility of developing novel hDHODH based treatments for Acute Myelogenous Leukemia (AML).
Conclusion: The review will describe a variety of specific inhibitor classes and conclude on recent and future therapeutic perspectives for this target.
Export Options
About this article
Cite this article as:
Lolli L. Marco, Sainas Stefano , Pippione C. Agnese , Giorgis Marta , Boschi Donatella and Dosio Franco *, Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy, Recent Patents on Anti-Cancer Drug Discovery 2018; 13 (1) . https://dx.doi.org/10.2174/1574892812666171108124218
DOI https://dx.doi.org/10.2174/1574892812666171108124218 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design of Cathepsin K Inhibitors for Osteoporosis
Current Topics in Medicinal Chemistry Structure, Function and Control of Complement C5 and its Proteolytic Fragments
Current Molecular Medicine Efficacy of Anti-TNF in Crohns Disease: How Does it Work?
Current Drug Targets IL-19 as a Potential Therapeutic in Autoimmune and Inflammatory Diseases
Current Pharmaceutical Design Molecular Recognition of Tachykinin Receptor Selective Agonists: Insights from Structural Studies
Mini-Reviews in Medicinal Chemistry Development of Vasculature Targeting Strategies for the Treatment of Chronic Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research Metal-Based Antimicrobial Protease Inhibitors
Current Medicinal Chemistry Nanotechnology on Duty in Medical Applications
Current Pharmaceutical Biotechnology Role of Bone Marrow in the Pathogenesis of Rheumatoid Arthritis
Current Rheumatology Reviews Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Patent Selections
Recent Patents on Anti-Infective Drug Discovery Editorial (Hot Topic: Anti-Inflammatory Drugs and the Heart Special Thematic)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Immunobiologic Agents in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthesis and Medicinal Applications of Benzimidazoles: An Overview
Current Organic Synthesis Editorial [Hot Topic: The Adenosinergic System - From Physiology to Pathology and Therapeutics (Guest Editors: A. Rees and J. Ham)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Lymphatics and Inflammation
Current Medicinal Chemistry Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Interstitial Lung Disease in Myositis
Current Respiratory Medicine Reviews Risk Factors for Lung Cancer in Never Smokers: A Recent Review Including Genetics
Current Respiratory Medicine Reviews